Clinical Study: Type 1 Diabetes (T1D)

TrialNet Pathway to Prevention Study

TrialNet Diabetes Risk Screening is available and free to eligible family members of people with type 1 diabetes through an international research effort and BRI.

PI: Carla J Greenbaum, MD
Email: Diabetes@BenaroyaResearch.org
Phone: 800.888.4187

T1D News

News Science in Seattle

Science in Seattle: A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab

Read the publication ➡
News Main Image - Puget Sound Business Journal

Benaroya Research Institute’s Dr. Carla Greenbaum Receives Puget Sound Business Journal Lifetime Achievement Award

Read More
News Scripps Research

Monitoring T cells may allow prevention of type 1 diabetes

Read More ➡

T1D Blog Stories

Blog Main Image - Researcher Woman Examining Samples Blue
January 10, 2024

On the Brink of a Golden Age of Medicine

"I know we will reach that golden age, and BRI’s research in human immunology is the vehi¬cle that will take us there. This field has shepherded incredible advances in recent years, including new vaccines, new cancer treatments, and new and better treatment options for autoimmune disease."
Read Article
Blog Main Mikaela Horse Editorial
September 25, 2023

Participants Like Mikaela Fuel Research Advances

Participating in a clinical trial for type 1 diabetes (T1D) was easy for 9-year-old Mikaela. “Everyone was really nice. I just had to drink a milkshake with some medicine in it and get an IV.
Read Article
Feature - Clinical Research Subject Blue
September 19, 2023

An Insider's Look Into Clinical Trials at BRI

Before medicines become widely available, they have to be rigorously tested — first in the lab, then in people through clinical trials.
Read Article

Study Summary

TrialNet is screening relatives of people with type 1 diabetes to find out if these family members are at risk for developing diabetes. Relatives of people with type 1 diabetes have about a three to four percent chance of testing positive for autoantibodies associated with diabetes.

If you learn you are at risk for developing type 1 diabetes, additional tests will be offered to estimate your chances of developing type 1 diabetes. If you qualify, you may have an opportunity to enroll in a prevention trial. All research volunteers will be closely monitored for early detection of type 1 diabetes. Early detection of type 1 diabetes may improve your blood sugar control and reduce your chances of developing complications. You will be part of a research program that may help other people at risk for type 1 diabetes.

Eligibility Criteria

The following people may be eligible:

  • Individuals who are 2.5-45 years of age with a parent, child, brother or sister with type 1 diabetes
  • Individual who are 2.5-20 years of age with a niece, nephew, aunt, uncle, grandparent, half-sibling or cousin with type 1 diabetes

Note: A relative diagnosed before the age of 40 AND started on insulin within the first year of diagnosis may have type 1 diabetes.

What will study participants be asked to do?

Screening involves a simple blood test for the presence of diabetes-related autoantibodies that may appear years before type 1 diabetes symptoms develop. TrialNet has established screening sites throughout North America.